Outcomes of infants* born in 2021 to persons with hepatitis B and managed by the CDC Perinatal Hepatitis B Prevention Program through the end of 2022 — 64 US Jurisdictions

Print
Related Pages
◀ Figure 4.1
Appendix ▶

Outcomes of infants* born in 2021 to persons with hepatitis B and managed by the CDC Perinatal Hepatitis B Prevention Program through the end of 2022, 64 US Jurisdictions

Outcomes of infants born in 2021 to persons with hepatitis B and managed by the CDC Perinatal Hepatitis B Prevention Program through the end of 20222021 in 64 United States jurisdictions.
Hepatitis B vaccine administration Post-vaccination serologic testing
Jurisdiction All infants managed* HBIG & vaccine at birth Complete series by 12 months of age Complete series after 12 months of age Total with complete series Received† HBsAg positive Immune§
No. No. % No. % No. % No. % No. % No. % No. %
Outcomes of infants born in 2018 to hepatitis B infected persons and managed by the CDC Perinatal Hepatitis B Prevention Program through the end of 2019, 64 U.S. Jurisdictions
All jurisdictions 7,102 6,718 95% 6,267 88% 97 1% 6,364 90% 4,631 65% 17 0% 4,412 95%
State
Alabama 95 12 13% 11 12% 1 1% 12 13% 8 8% 0 0% 7 88%
Alaska 28 28 100% 18 64% 0 0% 18 64% 6 21% 0 0% 6 100%
Arizona 117 101 86% 88 75% 6 5% 94 80% 65 56% 0 0% 63 97%
Arkansas 43 43 100% 41 95% 2 5% 43 100% 30 70% 0 0% 24 80%
California 1,070 1,039 97% 991 93% 7 1% 998 93% 667 62% 2 0% 629 94%
Colorado 97 93 96% 88 91% 2 2% 90 93% 69 71% 0 0% 63 91%
Connecticut 54 47 87% 53 98% 0 0% 53 98% 16 30% 0 0% 8 50%
Delaware 38 37 97% 16 42% 7 18% 23 61% 22 58% 0 0% 21 95%
Florida 238 208 87% 179 75% 4 2% 183 77% 53 22% 0 0% 48 91%
Georgia 232 225 97% 219 94% 2 1% 221 95% 200 86% 0 0% 195 98%
Hawaii 88 88 100% 85 97% 0 0% 85 97% 80 91% 0 0% 79 99%
Idaho 12 10 83% 7 58% 1 8% 8 67% 7 58% 0 0% 6 86%
Illinois 127 124 98% 126 99% 0 0% 126 99% 86 68% 0 0% 84 98%
Indiana 92 92 100% 88 96% 0 0% 88 96% 84 91% 0 0% 84 100%
Iowa 88 87 99% 84 95% 0 0% 84 95% 69 78% 0 0% 67 97%
Kansas 49 48 98% 48 98% 0 0% 48 98% 31 63% 0 0% 26 84%
Kentucky 84 82 98% 69 82% 6 7% 75 89% 22 26% 0 0% 21 95%
Louisiana 63 41 65% 44 70% 3 5% 47 75% 43 68% 0 0% 40 93%
Maine 10 10 100% 9 90% 0 0% 9 90% 7 70% 0 0% 7 100%
Maryland 167 159 95% 117 70% 20 12% 137 82% 135 81% 0 0% 135 100%
Massachusetts 204 202 99% 194 95% 0 0% 194 95% 172 84% 1 1% 165 96%
Michigan 111 111 100% 110 99% 0 0% 110 99% 101 91% 0 0% 101 100%
Minnesota 327 326 100% 314 96% 4 1% 318 97% 243 74% 2 1% 231 95%
Mississippi 50 49 98% 39 78% 2 4% 41 82% 27 54% 0 0% 26 96%
Missouri 78 75 96% 73 94% 1 1% 74 95% 47 60% 0 0% 46 98%
Montana 3 3 100% 3 100% 0 0% 3 100% 3 100% 0 0% 3 100%
Nebraska 38 38 100% 33 87% 0 0% 33 87% 32 84% 0 0% 32 100%
Nevada 53 51 96% 50 94% 1 2% 51 96% 28 53% 0 0% 26 93%
New Hampshire 18 18 100% 17 94% 1 6% 18 100% 5 28% 0 0% 5 100%
New Jersey 186 158 85% 93 50% 1 1% 94 51% 63 34% 0 0% 43 68%
New Mexico 14 13 93% 14 100% 0 0% 14 100% 10 71% 0 0% 9 90%
New York 232 226 97% 226 97% 2 1% 228 98% 194 84% 0 0% 190 98%
North Carolina 135 131 97% 124 92% 5 4% 129 96% 104 77% 1 1% 100 96%
North Dakota 36 36 100% 36 100% 0 0% 36 100% 15 42% 0 0% 15 100%
Ohio 200 181 90% 183 92% 1 0% 184 92% 88 44% 0 0% 83 94%
Oklahoma 77 73 95% 63 82% 0 0% 63 82% 33 43% 0 0% 22 67%
Oregon 49 41 84% 39 80% 3 6% 42 86% 32 65% 1 3% 29 91%
Pennsylvania 163 159 98% 163 100% 0 0% 163 100% 142 87% 0 0% 138 97%
Rhode Island 23 23 100% 23 100% 0 0% 23 100% 23 100% 0 0% 23 100%
South Carolina 54 53 98% 49 91% 0 0% 49 91% 32 59% 0 0% 32 100%
South Dakota 16 16 100% 12 75% 0 0% 12 75% 7 44% 0 0% 7 100%
Tennessee 98 93 95% 95 97% 1 1% 96 98% 68 69% 1 1% 64 94%
Texas 550 512 93% 425 77% 1 0% 426 77% 276 50% 0 0% 264 96%
Utah 63 63 100% 57 90% 0 0% 57 90% 39 62% 1 3% 37 95%
Vermont 9 5 56% 7 78% 0 0% 7 78% 0 0% 0 0
Virginia 189 184 97% 177 94% 2 1% 179 95% 119 63% 0 0% 118 99%
Washington 215 210 98% 195 91% 4 2% 199 93% 132 61% 0 0% 126 95%
West Virginia 11 10 91% 11 100% 0 0% 11 100% 11 100% 0 0% 11 100%
Wisconsin 86 85 99% 81 94% 3 3% 84 98% 55 64% 1 2% 53 96%
Wyoming 1 1 100% 1 100% 0 0% 1 100% 1 100% 0 0% 1 100%
Cities**
Chicago 55 55 100% 52 95% 0 0% 52 95% 36 65% 1 3% 34 94%
District of Columbia 18 17 94% 18 100% 0 0% 18 100% 15 83% 0 0% 13 87%
Houston 88 82 93% 86 98% 0 0% 86 98% 56 64% 0 0% 53 95%
New York City 663 660 100% 644 97% 1 0% 645 97% 606 91% 2 0% 591 98%
Philadelphia 101 97 96% 98 97% 0 0% 98 97% 87 86% 0 0% 85 98%
San Antonio 35 30 86% 31 89% 1 3% 32 91% 19 54% 0 0% 17 89%
Territories
American Samoa 2 2 100% 1 50% 1 50% 2 100% 0 0% 0 0% 0 0%
Guam 7 7 100% 2 29% 1 14% 3 43% 0 0% 0 0% 0 0%
N. Mariana Islands 7 6 86% 6 86% 0 0% 6 86% 6 86% 0 0% 6 100%
Puerto Rico 1 1 100% 1 100% 0 0% 1 100% 0 0% 0 0% 0 0%
Virgin Islands 2 2 100% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%
Freely associated states
Republic of the Marshall Islands 12 12 100% 12 100% 0 0% 12 100% 0 0% 0 0% 0 0%
The Federated States of Micronesia 19 16 84% 17 89% 0 0% 17 89% 0 0% 0 0% 0 0%
Republic of Palau 11 11 100% 11 100% 0 0% 11 100% 4 36% 4 100% 0 0%
Download Data (xlsx)

Source: National Perinatal Hepatitis B Prevention Program (PHBPP), Immunization Services Division, CDC.

* These data only include infants followed by the CDC Perinatal Hepatitis B Prevention Program. National and jurisdictional level HepB vaccination coverage rates are available via annual The Morbidity and Mortality Weekly Report (MMWR) publications of National Immunization Survey data and via VaxView.
† Post-vaccination serologic testing (PVST) includes a test for HBsAg, anti-HBs, or both. Results from PVST may be reported as HBsAg positive, HBsAg negative and immune or not immune, or indeterminate.
§ Anti-HBs ≥10 mIU/mL.
¶ Percentage is among infants that completed the vaccine series and received PVST.
** City data are mutually exclusive from state data.
HBIG: Hepatitis B immune globulin.
HepB: Hepatitis B vaccine.
HBsAg: Hepatitis B surface antigen.
anti-HBs: Antibody to hepatitis B surface antigen.

This table summarizes outcome data on infants born to persons with hepatitis B from the CDC Perinatal Hepatitis B Prevention Program (PHBPP). The 2021 birth cohort includes infants born in 2021 and followed through December 31, 2022.

Among the 7,102 infants whose care was managed by the PHBPP, 95% received recommended prophylaxis at birth, 90% completed the vaccine series (regardless of prophylaxis), and 65% received recommended post-vaccination serologic testing.

Among infants who received post-vaccination testing (n = 4,631), there were 17 (0.4%) cases of perinatal hepatitis B transmission.

Perinatal Hepatitis B figures and tables